Study Title
PEPN2121: A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Protocol ID
PEPN2121
Condition/s
Atypical Teratoid/Rhabdoid Tumor
Epithelioid Sarcoma
Kidney Medullary Carcinoma
Malignant Solid Neoplasm
Poorly Differentiated Chordoma
Recurrent Atypical Teratoid/Rhabdoid Tumor
Recurrent Chordoma
Recurrent Epithelioid Sarcoma
Recurrent Kidney Medullary Carcinoma
Recurrent Malignant Solid Neoplasm
Recurrent Rhabdoid Tumor
Refractory Atypical Teratoid/Rhabdoid Tumor
Refractory Chordoma
Refractory Epithelioid Sarcoma
Refractory Kidney Medullary Carcinoma
Refractory Malignant Solid Neoplasm
Refractory Rhabdoid Tumor
Rhabdoid Tumor
Epithelioid Sarcoma
Kidney Medullary Carcinoma
Malignant Solid Neoplasm
Poorly Differentiated Chordoma
Recurrent Atypical Teratoid/Rhabdoid Tumor
Recurrent Chordoma
Recurrent Epithelioid Sarcoma
Recurrent Kidney Medullary Carcinoma
Recurrent Malignant Solid Neoplasm
Recurrent Rhabdoid Tumor
Refractory Atypical Teratoid/Rhabdoid Tumor
Refractory Chordoma
Refractory Epithelioid Sarcoma
Refractory Kidney Medullary Carcinoma
Refractory Malignant Solid Neoplasm
Refractory Rhabdoid Tumor
Rhabdoid Tumor
Diagnosis Stage
Newly diagnosed
Relapsed/Refractory
Relapsed/Refractory
Location
QLD
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Open
Sites
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Months and older
International registry ID's
NCT05286801
| Study Title | PEPN2121: A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors |
|---|---|
| Protocol ID | PEPN2121 |
| Disease (Sub Disease) | Atypical Teratoid/Rhabdoid Tumor Epithelioid Sarcoma Kidney Medullary Carcinoma Malignant Solid Neoplasm Poorly Differentiated Chordoma Recurrent Atypical Teratoid/Rhabdoid Tumor Recurrent Chordoma Recurrent Epithelioid Sarcoma Recurrent Kidney Medullary Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Rhabdoid Tumor Refractory Atypical Teratoid/Rhabdoid Tumor Refractory Chordoma Refractory Epithelioid Sarcoma Refractory Kidney Medullary Carcinoma Refractory Malignant Solid Neoplasm Refractory Rhabdoid Tumor Rhabdoid Tumor |
| Diagnosis Stage | Newly diagnosed Relapsed/Refractory |
| Location | QLD |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT05286801 |
| Trial Status | Open |
| Trial Open Date | 16/08/2024 |
| Sites | Queensland Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 12 Months and older |
| International registry ID's | NCT05286801 |